Showing 1771-1780 of 2050 results for "".
- Belkin Laser Completes Enrollment of its GLAUrious Pivotal Trial for Glaucoma Laser Treatment in Secondshttps://modernod.com/news/belkin-laser-completes-enrollment-of-its-glaurious-pivotal-trial-for-glaucoma-laser-treatment-in-seconds/2479174/Belkin Laser announced that it has completed enrollment in its GLAUrious randomized controlled trial. In this confirmatory, prospective, non-inferiority, observer-masked RCT, a total of 192 patients were randomized across two arms, SLT and DSLT. 6-month follow-up for primary endpoint is ex
- Alcon Presents Highlights of ARVO 2021 Datahttps://modernod.com/news/alcon-presents-highlights-of-arvo-2021-data/2479149/Alcon will be presenting new data at the Association for Research in Vision and Ophthalmology (ARVO) Virtual Meeting (May 1-7). Presentations include data for the Systane iLux MGD Thermal Pulsation System, Precision1 daily disposable contact lenses, and a forthcoming reusable monthly contact lens
- Lumenis Receives FDA Approval for Its IPL Device to Manage Dry Eye Disease and Launches OptiLighthttps://modernod.com/news/lumenis-receives-fda-approval-for-its-ipl-device-to-manage-dry-eye-disease-and-launches-optilight/2479143/Lumenis announced that the FDA has granted De Novo authorization for Lumenis’ newest intense pulsed light (IPL) device for improving signs of dry eye disease due to meibomian gland dysfunction (MGD). The Lumenis multicenter, double-blinded, randomized controlled FDA trial showed that
- Okogen Announces Interim Analysis Results From RUBY Phase 2 Trial for Acute Adenoviral Conjunctivitis Drug Candidatehttps://modernod.com/news/okogen-announces-interim-analysis-results-from-ruby-phase-2-trial-for-acute-adenoviral-conjunctivitis-drug-candidate/2479140/Okogen announced the interim analysis results from RUBY, the company’s phase 2, double-masked, placebo-controlled clinical trial evaluating the safety and efficacy of OKG-0301 in patients with acute adenoviral conjunctivitis. In 58 patients diagnosed with acute adenoviral conjunctivitis, OKG-0301
- Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Trial of AR-15512 for the Treatment of Patients with Dry Eye Diseasehttps://modernod.com/news/aerie-pharmaceuticals-completes-enrollment-of-its-phase-2b-clinical-trial-of-ar-15512-trpm8-agonist-for-the-treatment-of-patients-with-dry-eye-disease/2479134/Aerie Pharmaceuticals announced the completion of patient enrollment for COMET-1, a phase 2b clinical trial of AR-15512 (TRPM8 Agonist) ophthalmic solution for the treatment of patients with dry eye disease. The first patient to enter this randomized, double-masked, vehicle-controlled phas
- Moderna’s COVID-19 Vaccine Shows Sustained Protection at Six Monthshttps://modernod.com/news/modernas-covid-19-vaccine-shows-sustained-protection-at-six-months/2479079/Moderna announced longer-term data Tuesday from the phase 3 trial used to support authorizations of its coronavirus vaccine mRNA-1272, saying the vaccine continues to show more than 90% efficacy against cases of COVID-19, including 95% protection from severe disease, a median 6 months after the s
- FDA Approves Bausch + Lomb ClearVisc Dispersive Ophthalmic Viscosurgical Device (OVD)https://modernod.com/news/fda-approves-bausch-lomb-clearvisc-dispersive-ophthalmic-viscosurgical-device-ovd/2479058/Bausch + Lomb, announced that the FDA has approved ClearVisc dispersive ophthalmic viscosurgical device (OVD) for use in ophthalmic surgery. “OVDs play a critical role in ophthalmic surgery, and ClearVisc offers surgeons unique advantages that are designed to contribute to surgical safety
- Pfizer, Moderna COVID-19 Vaccines Show High Efficacy in First US Real-World Studyhttps://modernod.com/news/pfizer-moderna-covid-19-vaccines-show-high-efficacy-in-first-us-real-world-study/2479028/New data released Monday from a US Centers for Disease Control and Prevention (CDC) study of vaccinated health care workers show that mRNA-based coronavirus vaccines by Pfizer and Moderna were 80% effective at preventing infections after one dose, with efficacy climbing to 90% 2 weeks after the s
- Nidek Launches RT-6100 CB for Windows to Enhance Refraction Workflowhttps://modernod.com/news/nidek-launches-rt-6100-cb-for-windows-to-enhance-refraction-workflow/2478994/Nidek has announced the launch of RT-6100 CB for Windows, an optional control software for the RT-6100 Intelligent Refractor and the TS-610 Tabletop Refraction System. As the environment is shifting and the dem
- After the American Academy of Ophthalmology’s Urging, Blue Cross Blue Shield Clarifies Eylea Policyhttps://modernod.com/news/after-the-american-academy-of-ophthalmologys-urging-blue-cross-blue-shield-clarifies-eylea-policy/2478988/Blue Cross Blue Shield informed the American Academy of Ophthalmology (AAO) of their updated policy on Eylea treatment to allow for continued coverage of patients who have lost three lines of vision on an eye chart, according to an AAO news release. The American Academy of Ophthalmology ha